Published in

Oxford University Press, Clinical Infectious Diseases, p. ciw846, 2016

DOI: 10.1093/cid/ciw846

Links

Tools

Export citation

Search in Google Scholar

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program

Journal article published in 2016 by Andreoni Massimo, SIMIT (Società Italiana di Malattie Infettivee Tropicali), Elisabetta Teti, Andrea Antinori, Laura Milazzoi, Savatore Sollima, Raffaele Bruno, Giuliano Rizzardini, Antonio Di Biagio, Annalisa Saracino, Vanni Borghi, Gloria Taliani, Andrea De Luca, Antonella D'Arminio Monforte, Claudio Maria Mastroianni and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).